Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Ropinirole Clear all

Conditions: Parkinson Disease
Interventions: Ropinirole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 28
States / cities: Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more

Conditions: Cocaine Dependence
Interventions: levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sexual Dysfunction
Interventions: Ropinirole (Requip); Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Restless Legs Syndrome
Interventions: pramipexole; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Advanced Idiopathic Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more

Conditions: Parkinson Disease
Interventions: ropinirole monotherapy, placebo monotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 11
States / cities: Fountain Valley, California • Pasadena, California • Reseda, California + 8 more

Conditions: Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions: Rotigotine; Drug
Lead sponsor: John Winkelman, MD, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions: ropinirole controlled-release (REQUIP CR) for RLS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more

Conditions: Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions: ropinirole CR-RLS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 45
States / cities: Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more

Conditions: Restless Legs Syndrome
Interventions: ropinirole dosing for up to 28 days; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Restless Legs Syndrome
Interventions: Ropinirole Immediate Release; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Macon, Georgia • Chicago, Illinois + 4 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Safinamide (as add-on therapy); Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oxnard, California + 27 more

Conditions: Depressive Disorder, Major
Interventions: Ropinirole CR; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Stanford, California

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole IR 1 mg Placebo, Ropinirole IR 2 mg Placebo, Ropinirole CR 2 mg, Ropinirole CR 3 mg, Ropinirole CR 2 mg Placebo, Ropinirole CR 3 mg Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more

Conditions: Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Interventions: ropinirole Extended Release (XR); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 28
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 25 more

Search by objective public record fields.

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

Cognitive Remediation for Cocaine Dependence

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

Ropinirole 0.25 mg Tablets Under Fasting Conditions

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

Switching From Oral Dopamine Agonists to Rotigotine

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole